Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules

MT Newswires Live05-19 05:01

Neurocrine Biosciences' (NBIX) Ingrezza, or valbenazine, capsules delivered improvements in uncontrolled movements and functional status in patients with tardive dyskinesia based on new data from a clinician survey, the company said late Monday.

Tardive dyskinesia is a neurological condition that involves involuntary movements.

In a subgroup analysis, nearly all people with the condition treated with the drug experienced fewer uncontrolled movements, and most showed an improvement in symptoms within four weeks, the company said.

Additionally, patients treated with the drug demonstrated "widespread improvements in functional status, independence, ability to perform daily activities and ability to work," Neurocrine said.

The results are being presented at the American Psychiatric Association annual meeting, which is taking place from May 16 to May 20 in San Francisco, the company said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2636001372?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-19 05:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636001372","market":"us","top_or_hot":-1,"title":"Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules","media":"MT Newswires Live","content":"<html><body><p> Neurocrine Biosciences' (NBIX) Ingrezza, or valbenazine, capsules delivered improvements in uncontrolled movements and functional status in patients with tardive dyskinesia based on new data from a clinician survey, the company said late Monday.</p><p>Tardive dyskinesia is a neurological condition that involves involuntary movements.</p><p>In a subgroup analysis, nearly all people with the condition treated with the drug experienced fewer uncontrolled movements, and most showed an improvement in symptoms within four weeks, the company said.</p><p>Additionally, patients treated with the drug demonstrated \"widespread improvements in functional status, independence, ability to perform daily activities and ability to work,\" Neurocrine said.</p><p>The results are being presented at the American Psychiatric Association annual meeting, which is taking place from May 16 to May 20 in San Francisco, the company said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurocrine Biosciences Says Data Show Functional Improvement in Tardive Dyskinesia With Ingrezza Capsules\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-05-19 05:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Neurocrine Biosciences' (NBIX) Ingrezza, or valbenazine, capsules delivered improvements in uncontrolled movements and functional status in patients with tardive dyskinesia based on new data from a clinician survey, the company said late Monday.</p><p>Tardive dyskinesia is a neurological condition that involves involuntary movements.</p><p>In a subgroup analysis, nearly all people with the condition treated with the drug experienced fewer uncontrolled movements, and most showed an improvement in symptoms within four weeks, the company said.</p><p>Additionally, patients treated with the drug demonstrated \"widespread improvements in functional status, independence, ability to perform daily activities and ability to work,\" Neurocrine said.</p><p>The results are being presented at the American Psychiatric Association annual meeting, which is taking place from May 16 to May 20 in San Francisco, the company said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0889565916.HKD","symbol_name":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636001372","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636001372","pubTimestamp":1779138107,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurocrine Biosciences'  Ingrezza, or valbenazine, capsules delivered improvements in uncontrolled movements and functional status in patients with tardive dyskinesia based on new data from a clinician survey, the company said late Monday.Tardive dyskinesia is a neurological condition that involves involuntary movements.In a subgroup analysis, nearly all people with the condition treated with the drug experienced fewer uncontrolled movements, and most showed an improvement in symptoms within four weeks, the company said.Additionally, patients treated with the drug demonstrated \"widespread improvements in functional status, independence, ability to perform daily activities and ability to work,\" Neurocrine said.The results are being presented at the American Psychiatric Association annual meeting, which is taking place from May 16 to May 20 in San Francisco, the company said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2065170008.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU2065171311.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) ACC","LU2065169927.USD":"M&G (LUX) GLOBAL MAXIMA \"A\" (USD) ACC","LU2065171402.SGD":"M&G (LUX) GLOBAL MAXIMA \"A\" (SGD) INC","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","NBIX":"神经分泌生物科学","BK4139":"生物科技","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC"},"translate_title":"Neurocrine Biosciences表示，数据显示Ingrezza胶囊可改善迟发性运动障碍的功能","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NBIX":1.5},"content_text":"Neurocrine Biosciences' (NBIX) Ingrezza, or valbenazine, capsules delivered improvements in uncontrolled movements and functional status in patients with tardive dyskinesia based on new data from a clinician survey, the company said late Monday.Tardive dyskinesia is a neurological condition that involves involuntary movements.In a subgroup analysis, nearly all people with the condition treated with the drug experienced fewer uncontrolled movements, and most showed an improvement in symptoms within four weeks, the company said.Additionally, patients treated with the drug demonstrated \"widespread improvements in functional status, independence, ability to perform daily activities and ability to work,\" Neurocrine said.The results are being presented at the American Psychiatric Association annual meeting, which is taking place from May 16 to May 20 in San Francisco, the company said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2636001372","isCrawlerRequest":true}